Anti-IL-3Ra/CD123 Antibody (Talacotuzumab)
Catalog No.
F1218
Anti-IL-3Ra/CD123 Antibody (Talacotuzumab)
Featured Products
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized CD123 neutralizing monoclonal antibody with a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, and 16.8 nM for CD123, CD32b/c, CD16-158F, and CD16-158V, respectively. Talacotuzumab inhibits the binding of IL-3 to CD123, thereby antagonizing IL-3 signaling in target cells. Talacotuzumab mutates the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in reducing leukemic cell growth in an acute myeloid leukemia (AML) xenograft mouse model in vivo.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
147.42 kDa
Dry ice
1826831-79-1
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
JNJ-56022473, CSL362
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P26951
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human IL 3Rα His at 2 ug/mL can bind Anti-IL-3Ra/CD123 Antibody (Talacotuzumab)
IL-3Ra / CD123
Please avoid freeze-thaw cycles.